Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$22.6 million.

  • Vanda Pharmaceuticals' Net Income towards Common Stockholders fell 32422.99% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.2 million, marking a year-over-year decrease of 41384.87%. This contributed to the annual value of -$18.9 million for FY2024, which is 85328.82% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Net Income towards Common Stockholders is -$22.6 million, which was down 32422.99% from -$27.2 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $9.6 million during Q2 2021, with a 5-year trough of -$29.5 million in Q1 2025.
  • In the last 5 years, Vanda Pharmaceuticals' Net Income towards Common Stockholders had a median value of $180000.0 in 2023 and averaged -$3.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 185646.26% in 2021, then plummeted by 305777.78% in 2024.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Net Income towards Common Stockholders stood at $7.1 million in 2021, then dropped by 2.96% to $6.9 million in 2022, then crashed by 134.71% to -$2.4 million in 2023, then crashed by 105.44% to -$4.9 million in 2024, then plummeted by 359.81% to -$22.6 million in 2025.
  • Its Net Income towards Common Stockholders was -$22.6 million in Q3 2025, compared to -$27.2 million in Q2 2025 and -$29.5 million in Q1 2025.